SeraNovo Appoints Michiel Van Speybroeck as Chief Development Officer

We are thrilled to announce the appointment of Michiel Van Speybroeck as our Chief Development Officer. 

 

Over the last 10 years, Michiel has held technical leadership positions in the pharmaceutical contract development and manufacturing industry. Most recently, he was Corporate Technology Officer at Ardena, where he was responsible for the technical integration of the company’s services and the management of cross-functional chemical-pharmaceutical development programs in support of early-phase clinical studies. Prior to that, he was Head of Formulation at Ardena. In this position, he was accountable for the company’s dosage form design and development strategy. Before joining Ardena, Michiel was R&D Director and subsequently Chief Scientific Officer at Formac Pharmaceuticals, where his main responsibility was to oversee the internal and external research and development programs evaluating the utility of the company’s proprietary solubility-enhancing drug delivery technology.

 

See the full press release here

This website uses cookies to track the usage of it.

More info